Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2014; 6(12): 836-843
Published online Dec 27, 2014. doi: 10.4254/wjh.v6.i12.836
Published online Dec 27, 2014. doi: 10.4254/wjh.v6.i12.836
Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma
Yoji Kishi, Kazuaki Shimada, Satoshi Nara, Minoru Esaki, Tomoo Kosuge, Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo 104-0045, Japan
Author contributions: All the authors contributed to the work.
Supported by Grant-in-aid from the 106th Annual Congress of the JSS Memorial Surgical Research Fund, Tokyo, Japan
Correspondence to: Yoji Kishi, MD, PhD, Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. yokishi@ncc.go.jp
Telephone: +81-33-5422511 Fax: +81-33-5423815
Received: July 31, 2014
Revised: September 30, 2014
Accepted: October 28, 2014
Published online: December 27, 2014
Processing time: 135 Days and 2.2 Hours
Revised: September 30, 2014
Accepted: October 28, 2014
Published online: December 27, 2014
Processing time: 135 Days and 2.2 Hours
Core Tip
Core tip: Previous studies comparing hepatectomy with other nonsurgical treatments for hepatocellular carcinoma (HCC) evaluated which provided superior survival benefit. However, considering the high recurrence rate after curative loco-regional treatment, and limited indications for hepatectomy because of background liver damage, it is important to recognize hepatectomy as a complement to other nonsurgical treatment, rather than a contraindication. A multidisciplinary approach combining and repeating different treatments prolongs patients’ survival with HCC, including those with recurrent or initially unresectable tumors.